SCHEMBL4240643

SCHEMBL4240643

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(CC)CC)cc4)cc3F)cc2OC)CC1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 1/20 0.42
FLT1 P17948 3/20 0.42
FLT4 P35916 3/20 0.42
KDR P35968 3/20 0.42
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
HTR4 Q13639 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GRM7 Q14831 1/20 0.39
SLC5A7 Q9GZV3 1/20 0.39
MCHR1 Q99705 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4240272 0.97 LMNA (0.42) PDE4DFLT1FLT4KDRLMNA
SCHEMBL4229188 0.92 MCHR1 (0.40) PDE4DFLT1FLT4KDRMAPT
SCHEMBL4237921 0.91 CCR3 (0.41) FLT1FLT4KDRLMNAPKM
SCHEMBL4238135 0.91 SMN1; SMN2 (0.41) PDE4DFLT1FLT4KDRMAPT
SCHEMBL4242226 0.90 SMN1; SMN2 (0.43) PDE4DFLT1FLT4KDRMAPT
SCHEMBL4233470 0.90 MCHR1 (0.40) FLT1FLT4KDRMAPTTAS1R3
SCHEMBL4690097 0.90 CCR3 (0.45) PDE4DFLT1FLT4KDRHTR4
SCHEMBL4686817 0.89 KDR (0.40) PDE4DFLT1FLT4KDRMAPT
SCHEMBL4236281 0.89 TAS1R3 (0.45) MAPTHTR4TAS1R3TAS1R1SMN1; SMN2
SCHEMBL4236698 0.89 SMN1; SMN2 (0.46) PDE4DLMNAMAPTHTR4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PDE4D 382/4885FLT1 1180/4885FLT4 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.